In last trading session, Predictive Oncology Inc. (NASDAQ:POAI) saw 0.12 million shares changing hands with its beta currently measuring 1.16. Company’s recent per share price level of $0.31 trading at $0.0 or 1.99% at ring of the bell on the day assigns it a market valuation of $23.59M. That closing price of POAI’s stock is at a discount of -254.84% from its 52-week high price of $1.10 and is indicating a premium of 32.26% from its 52-week low price of $0.21. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.29 million shares which gives us an average trading volume of 272.78K if we extend that period to 3-months.
Predictive Oncology Inc. (NASDAQ:POAI) trade information
Upright in the green during last session for gaining 1.99%, in the last five days POAI remained trading in the green while hitting it’s week-highest on Tuesday, 11/22/22 when the stock touched $0.31 price level, adding 10.14% to its value on the day. Predictive Oncology Inc.’s shares saw a change of -67.11% in year-to-date performance and have moved 14.90% in past 5-day. Predictive Oncology Inc. (NASDAQ:POAI) showed a performance of 15.66% in past 30-days. Number of shares sold short was 0.13 million shares which calculate 0.54 days to cover the short interests.
Predictive Oncology Inc. (POAI) estimates and forecasts
Statistics highlight that Predictive Oncology Inc. is scoring comparatively higher than the scores of other players of the relevant industry. The company lost -13.48% of value to its shares in past 6 months, showing an annual growth rate of 13.04% while that of industry is -4.60. Apart from that, the company came raising its revenue forecast for fiscal year 2022. This year revenue growth is estimated to rise 745.10% from the last financial year’s standing.
1 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of $2 million for the same. And 1 analysts are in estimates of company making revenue of $4 million in the next quarter that will end on Sep 2022. Company posted $600k and $314k of sales in current and next quarters respectively a year earlier. Analysts are expecting this quarter sales to grow by 233.30% while estimating it to be 1,173.90% for the next quarter.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 56.50% during past 5 years.
Predictive Oncology Inc. is more likely to be releasing its next quarterly report on November 11 and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.
Predictive Oncology Inc. (NASDAQ:POAI)’s Major holders
Insiders are in possession of 4.12% of company’s total shares while institution are holding 5.79 percent of that, with stock having share float percentage of 6.04%. Investors also watch the number of corporate investors in a company very closely, which is 5.79% institutions for Predictive Oncology Inc. that are currently holding shares of the company. Vanguard Group, Inc. (The) is the top institutional holder at POAI for having 2.13 million shares of worth $0.87 million. And as of Jun 29, 2022, it was holding 2.71% of the company’s outstanding shares.
The second largest institutional holder is Geode Capital Management, LLC, which was holding about 0.65 million shares on Jun 29, 2022. The number of shares represents firm’s hold over 0.82% of outstanding shares, having a total worth of $0.27 million.
On the other hand, Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund are the top two Mutual Funds which own company’s shares. As of Jun 29, 2022, the former fund manager was holding 1.39 million shares of worth $0.57 million or 1.77% of the total outstanding shares. The later fund manager was in possession of 0.71 million shares on Jun 29, 2022, making its stake of worth around $0.29 million in the company or a holder of 0.91% of company’s stock.